Increased levels of baseline circulating kidney injury marker-1 (KIM-1) are associated with worse clinical outcomes for patients receiving nivolumab plus ipilimumab (nivo/ipi) or sunitinib alone in the CheckMate 214 study, according to research presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium. Results were presented by Wenxin Xu, MD, of Dana-Farber Cancer Institute and Harvard Medical School. ...
Renal Cell Carcinoma Diagnostics
Advertisement
Dr. Dan Joyce discusses key SUO studies on RCC prognostics, personalized medicine, and advancements in treatment strategies.
Dr. Karam explains the main points of emphasis when it comes to small renal masses and surveillance versus surgery.
Serial ctDNA negativity or clearance was linked to improved PFS compared with persistent ctDNA positivity during treatment.
The phase 3 ZIRCON trial demonstrated positive results with use of the agent for patients with ccRCC.
Dr. Brian Shuch gives a preview of Urology on the Beach 2025, including his session on molecular imaging agents.
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Higher PSMA expression in non-metastatic ccRCC correlates with improved progression-free survival, study shows.
For the study, researchers identified potential protein biomarkers for diagnosing and prognosticating renal cell carcinoma.
Machine learning models can help with clinical decision making regarding renal function, according to new data.
[⁸⁹Zr]Zr-girentuximab PET-CT ccRCC prognostic imaging has a favorable safety profile and is highly accurate.
Advertisement
Video Insights
Conferene Coverage
Dr. Keizman showcases his research on using Decipher for early prostate cancer for USA versus non-USA populations.
Dr. Ghoreifi characterizes the activity of inflammasome genes and their association with oncological outcomes in PC.
Drs. Ghatalia and Nizam break down in detail the RETAIN-2 study, a phase 2 trial of risk enabled therapy for MIBC.
EV+P continues to show superior efficacy and durable responses in previously untreated locally advanced or metastatic UC.
The study found promising results with lenvatinib + belzutifan for patients with previously treated RCC.
Dr. Galsky highlights the latest findings on the impact of pCR on long-term outcomes in the NIAGARA trial.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.